文献速递骨软组织肉瘤与黑色素瘤

高危黑色素瘤辅助抗PD-1治疗后慢性免疫相关不良事件

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项多中心回顾性队列研究纳入387例接受辅助抗PD-1治疗的III-IV期黑色素瘤患者,发现43.2%发生慢性irAE(停药后持续≥12周),其中96.4%为1-2级,85.6%持续至末次随访;内分泌病、关节炎、口干、神经毒性和眼部事件更易慢性化,而内脏器官irAE慢性化率较低。

要点

  • 辅助抗PD-1治疗后43.2%患者发生慢性irAE,绝大多数为低级别但常持续存在。
  • 内分泌病、关节炎、口干、神经毒性和眼部事件更易慢性化。
  • 年龄、性别、起病时间和是否需要类固醇与慢性化风险无关。

核心结论

  • 辅助抗PD-1治疗的慢性irAE比既往认识更常见,且即使延长随访也常持续存在,但多为低级别。

研究设计与样本

  • 2015-2020年美国与澳大利亚8家学术医疗中心开展的多中心回顾性队列研究,纳入387例接受辅助抗PD-1治疗的III-IV期黑色素瘤患者。

主要发现

  • 267例(69.0%)发生急性irAE,其中52例(19.5%)为3-5级,各1例发生致死性心肌炎和神经毒性。
  • 167例(43.2%)发生慢性irAE,其中161例(96.4%)为1-2级,143例(85.6%)持续至末次随访。
  • 内分泌病83.0%(73/88)、关节炎48.9%(22/45)、口干52.9%(9/17)、神经毒性73.3%(11/15)、眼部事件62.5%(5/8)易慢性化。
  • 结肠炎慢性化率13.6%(6/44),其中66.7%(4/6)经延长随访缓解。
  • 年龄、性别、起病时间和是否需要类固醇与irAE慢性化无关。

临床怎么用

  • 在辅助治疗决策中应充分考虑慢性irAE风险,并向患者说明多数为低级别但可能长期持续。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not been well defined. OBJECTIVE: To determine the incidence, time course, spectrum, and associations of chronic irAEs arising from adjuvant anti-PD-1 therapy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective multicenter cohort study was conducted between 2015 and 2020 across 8 academic medical centers in the United States and Australia. Patients with stage III to IV melanomas treated with anti-PD-1 in the adjuvant setting were included. MAIN OUTCOMES AND MEASURES: Incidence, types, and time course of chronic irAEs (defined as irAEs persisting at least 12 weeks after therapy cessation). RESULTS: Among 387 patients, the median (range) age was 63 (17-88) years, and 235 (60.7%) were male. Of these patients, 267 (69.0%) had any acute irAE, defined as those arising during treatment with anti-PD-1, including 52 (19.5%) with grades 3 through 5 events; 1 patient each had fatal myocarditis and neurotoxicity. Chronic irAEs, defined as those that persisted beyond 12 weeks of anti-PD-1 discontinuation, developed in 167 (43.2%) patients, of which most (n = 161; 96.4%) were mild (grade 1 or 2) and most persisted until last available follow-up (n = 143; 85.6%). Endocrinopathies (73 of 88; 83.0%), arthritis (22 of 45; 48.9%), xerostomia (9 of 17; 52.9%), neurotoxicities (11 of 15; 73.3%), and ocular events (5 of 8; 62.5%) were particularly likely to become chronic. In contrast, irAEs affecting visceral organs (liver, colon, lungs, kidneys) had much lower rates of becoming chronic irAEs; for example, colitis became chronic in 6 of 44 (13.6%) cases, of which 4 of 6 (66.7%) resolved with prolonged follow-up. Age, gender, time of onset, and need for steroids were not associated with the likelihood of chronicity of irAEs. CONCLUSION AND RELEVANCE: In this multicenter cohort study, chronic irAEs associated with anti-PD-1 therapy appear to be more common than previously recognized and frequently persisted even with prolonged follow-up, although most were low grade. The risks of chronic irAEs should be integrated into treatment decision-making.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Patrinely JR, Johnson R, Lawless AR, et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021. PMID: 33764387. doi:10.1001/jamaoncol.2021.0051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。